These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 33403970)

  • 41. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
    Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
    Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.
    Adenuga BA; Kibuule D; Rennie TW
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):247-253. PubMed ID: 31520574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
    Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
    Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
    Awodele O; Ibrahim A; Orhii P
    Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.
    Mouton JP; Mehta U; Parrish AG; Wilson DP; Stewart A; Njuguna CW; Kramer N; Maartens G; Blockman M; Cohen K
    Br J Clin Pharmacol; 2015 Oct; 80(4):818-26. PubMed ID: 25475751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda.
    Ndagije H; Nambasa V; Namagala E; Nassali H; Kajungu D; Sematiko G; Olsson S; Pal S
    Drug Saf; 2015 Apr; 38(4):395-408. PubMed ID: 25749663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency and preventability of adverse drug reactions in paediatric patients.
    Temple ME; Robinson RF; Miller JC; Hayes JR; Nahata MC
    Drug Saf; 2004; 27(11):819-29. PubMed ID: 15350153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parental reporting of adverse drug reactions in South Africa: An online survey.
    Pillay S; Mulubwa M; Viljoen M
    Afr J Prim Health Care Fam Med; 2021 Sep; 13(1):e1-e8. PubMed ID: 34636609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Assessment of an active pharmacovigilance system carried out by a pharmacist].
    Sánchez I; Amador C; Plaza JC; Correa G; Amador R
    Rev Med Chil; 2014 Aug; 142(8):998-1005. PubMed ID: 25424672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
    Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
    Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.
    Leone R; Moretti U; D'Incau P; Conforti A; Magro L; Lora R; Velo G
    Drug Saf; 2013 Apr; 36(4):267-76. PubMed ID: 23475583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria.
    Adisa R; Adeniyi OR; Fakeye TO
    Int J Clin Pharm; 2019 Aug; 41(4):1062-1073. PubMed ID: 31140162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa.
    Terblanche A; Meyer JC; Godman B; Summers RS
    Hosp Pract (1995); 2018 Oct; 46(4):221-228. PubMed ID: 30092683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.